RBC Raises Price Target on GRAIL, Inc.
RBC increased its price target for GRAIL, Inc. to $100 from $84 while maintaining a Sector Perform rating.
Stocks · News reference
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GRAIL, Inc. 12-Month Price Target Raised to $134.33
Analysts have increased the 12-month price target for GRAIL, Inc. to $134.33, maintaining a consensus "Buy" rating.
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL, Inc. released its financial results for the third quarter of 2026.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
GRAIL Q3 EPS $(2.21) Beats $(2.55) Estimate, Sales $37.269M Miss $44.346M Estimate
GRAIL to Present at the UBS Global Healthcare Conference
GRAIL, Inc. announced that company management is scheduled to present at the upcoming UBS Global Healthcare Conference in Palm Beach, Florida.